Matinas BioPharma Holdings, Inc.
Biopharma firm developing therapeutics using its Lipid Nanocrystal (LNC) platform.
MTNB | US
Overview
Corporate Details
- ISIN(s):
- US5768101058
- LEI:
- Country:
- United States of America
- Address:
- 1545 ROUTE 206 SOUTH, 7921 BEDMINSTER
Description
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics using its proprietary Lipid Nanocrystal (LNC) platform. This technology is designed to enable the safe, oral, and targeted intracellular delivery of a variety of molecules, including small molecules, nucleic acids, and small oligonucleotides. The company's lead product candidate, MAT2203, is an oral formulation of the antifungal drug amphotericin B. Matinas is also advancing discovery programs directed at oncology and inflammation.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Matinas BioPharma Holdings, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Matinas BioPharma Holdings, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Matinas BioPharma Holdings, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
